Shanmu Biotechnology

The firm specializes in AI-powered micro medical robots designed for the prediction, diagnosis, and management of chronic diseases. Its core product is the 'Perception Series' of home healthcare AI robots, described as one of the world's smallest fully automated chemistry analyzers. These devices are designed to be placed inside a toilet bowl to enable continuous and non-invasive health tracking through urine-based metabolic analysis. The technology utilizes microfluidic chipsets and multi-spectral systems to quantify over 10 urine biomarkers, including glucose and uric acid, providing data for self-management of chronic conditions, early disease detection, and guidance on prescriptions and diet.

Shanmu offers different reagent kits tailored to specific health needs, such as a Chronic Disease Management Kit for conditions like diabetes and chronic kidney disease, and a Female Health Management Kit for tracking menstrual cycles, ovulation, and pregnancy. The company targets individuals, families, and medical institutions with its digital healthcare solutions. As a venture capital-backed entity, Shanmu has received funding from investors including Green Pine Capital Partners, Innolink, Glacier Capital China, Langke Investment, and Wanwuwei Venture Capital.